Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab

Yoshiko Mizushina1,2 | Fumiyoshi Ohyanagi1,3 | Jun Shiihara1 | Motoko Nomura1 | Hiromitsu Ohta1 | Hisashi Oshiro4 | Hiroyoshi Tsubochi5,6 | Gen Kusaka7 | Yasuhiro Yamaguchi1

1Division of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan
2Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan
3Thoracic Oncology, Saitama Cancer Center, Saitama, Japan
4Department of Pathology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
5Division of Thoracic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan
6Department of Thoracic Surgery, Jichi Medical University, Tochigi, Japan
7Department of Neurosurgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan

Correspondence
Yoshiko Mizushina, Division of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya, Saitama, Saitama 330-8503, Japan.
Email: mizushina@jichi.ac.jp

Abstract
A 52-year-old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death-ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase fusion gene. However, brain metastasis and chest wall tumor relapse occurred. Considering insufficient improvement with gamma knife treatment for brain metastasis and combination chemotherapy (paclitaxel, carboplatin, and bevacizumab), pembrolizumab monotherapy and palliative irradiation therapy for chest metastases were started after brain tumor volume reduction using craniotomy. Brain edema and chest wall metastases markedly improved following a pseudoprogression of the brain edema accompanied by a performance status decline; this effect continued until 11 cycles of pembrolizumab administration.

Keywords
immune checkpoint inhibitor, lung cancer, pembrolizumab, pseudoprogression, spindle cell carcinoma

CASE REPORT
A 52-year-old man, who smoked 34 packs/year and was an ex-smoker, was diagnosed with a left lower lobe lung tumor and subsequently underwent pneumonectomy of the left lung. He was diagnosed with primary lung spindle cell carcinoma (SpCC; pT4aN1M0, stage III B), with programmed death-ligand 1 (PD-L1) expression (tumor proportion score [TPS] ≥95%) without epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase fusion gene (Figure 1). Brain metastasis in the right temporal lobe was observed nine months after pneumonectomy despite the patient receiving four cycles of cisplatin and vinorelbine as postoperative adjuvant chemotherapy (Figure 2(a),(b)). Brain metastasis was treated with gamma knife surgery. However, radiation necrosis was suspected because no reduction was observed in the tumor size and perifocal edema. Moreover, progressively increasing chest wall metastases appeared 10 months after pneumonectomy. Despite combination chemotherapy (paclitaxel, carboplatin, and bevacizumab) given as first line chemotherapy 14 months after pneumonectomy, his brain edema progressively worsened (Figure 2(c),(d)). Thus, craniotomy and brain tumor volume reduction were performed, with pathological examination revealing metastatic lung carcinoma with necrosis.

Throughout that period, chest wall metastases progressively increased in size; the patient had a performance status (PS) score of 2. Pembrolizumab monotherapy (200 mg/bodyweight, every three weeks) was started as second-line chemotherapy one month after craniotomy. Palliative irradiation therapy (30 Gy/10 fr) to the chest wall was also performed from Day 3 after pembrolizumab monotherapy initiation. From Day 1, he developed a severe fever and exhibited appetite loss, general fatigue, and consciousness...
impairment (drowsy state) (PS score increased to 4). On Day 8, brain computed tomography (CT) showed an exacerbation of the brain edema (Figure 3(a)). Given the lack of improvement in fever despite antibiotic treatment, the fever was suspected to be associated with the tumor or reactive against pembrolizumab. To control the fever, naproxen was administered. The fever and consciousness level gradually improved, and he was discharged on Day 30.

After two cycles of pembrolizumab monotherapy, the patient’s appetite and PS began to improve. Chest CT showed larger chest wall tumors than those after initial pembrolizumab administration (Figure 3(b)). His PS score improved to two after five cycles, and chest and brain CT showed reduction in the chest wall tumor size and brain edema (Figure 3(c),(d)).

After 12 and 15 cycles of pembrolizumab, brain magnetic resonance imaging showed new brain metastasis and chest wall tumor regrowth. Therefore, pembrolizumab monotherapy was stopped, and another round of gamma knife treatment for the brain metastases was performed. Despite recommending cytotoxic chemotherapies, the patient refused and died four months after pembrolizumab monotherapy.

**DISCUSSION**

This patient was diagnosed with lung SpCC via surgical tumor resection but developed recurrence nine months after pneumonectomy. The recurrent lesions were refractory to
irradiation and chemotherapy (cytotoxic chemotherapy and antiangiogenic treatment). In 2015, the World Health Organization classified pulmonary SpCC as a sarcomatoid carcinoma, comprising an almost pure population of epithelial spindle cells, without differentiated carcinomatous elements. Sarcomatoid carcinomas are rare (<1% of all lung cancers), have a poor prognosis, and are resistant to cytotoxic chemotherapy.\(^1,2\)

In the current case, the resected tumor showed high PD-L1 expression and a significant therapeutic response to pembrolizumab. Sarcomatoid carcinomas, including the sarcomatous area of pleomorphic carcinomas, show high PD-L1 expression and have poor prognosis.\(^3,4\)

Pembrolizumab, an immune checkpoint inhibitor (ICI), is a highly selective, humanized, immunoglobulin G4 monoclonal antibody against programmed cell death-1.\(^5\) Despite the proven efficacy of pembrolizumab monotherapy against PD-L1-expressing non-small cell lung cancer (NSCLC) with a TPS of ≥1%, information regarding its effects against lung SpCC is scarce.\(^5\) Meanwhile, pembrolizumab monotherapy effectively decreased lung and metastatic tumors in a patient with SpCC.\(^5\)

Furthermore, ICIs showed effects against sarcomatoid lung carcinoma and mesothelioma.\(^7,8\) The current case developed brain metastases, resistant to irradiation and exhibited radiation necrosis. Patients with NSCLC who develop brain metastases have a poor prognosis and survival.\(^9,10\) As metastatic brain tumors are protected by the blood–brain barrier (BBB), ICI efficacy remains unclear. BBB is often compromised in patients with brain metastases and is subsequently remodeled into a blood–tumor barrier, altering the immune cell population around brain metastases.\(^9,11,12\) Moreover, ICIs possibly exert a suppressive effect on the progression of central nervous system tumors despite no established evidence that demonstrate the efficacy of ICI against brain metastases.\(^9,11,12\) Therefore, pembrolizumab penetration into the brain tumor was possible in this case because BBB was disrupted by the preceding brain tumor resection.

In the current case, brain edema exacerbated with PS decline, following initial pembrolizumab administration. Initial ICI treatment for brain metastases often shows a pseudoprogression within the first three months.\(^9\) Pseudoprogression of brain metastases has been explained histologically by inflammatory cell infiltration, edema, and necrosis, and radiologically by frequent exhibition of perilesional brain edema.\(^16,18\) A careful therapeutic response evaluation is thus recommended to avoid progressive disease.
six months or less after ICI administration initiation. In retrospect, brain edema and chest wall tumor exacerbation after initial pembrolizumab administration may suggest a pseudoprogression given the remarkable therapeutic effect observed thereafter. Although it is difficult to distinguish the contribution of abscopal effect by palliative irradiation therapy to chest wall, exacerbation of brain edema could be explained adequately by pseudoprogression of ICI. Although brain edema exacerbation frequently induces PS decline, a pseudoprogression would usually exhibit a subsequent improvement. Therefore, a pseudoprogression should be considered to make appropriate decisions regarding ICI administration continuation.

Lung SpCC has a poor prognosis and is usually resistant to cytotoxic chemotherapy. Our findings suggest ICI therapy as a novel therapeutic strategy for lung SpCC. Furthermore, given that pseudoprogression with PS decline is commonly observed in brain metastases treated with ICIs, the therapeutic response should be carefully evaluated to determine whether ICI can be continued.

CONFLICT OF INTEREST
No authors report any conflict of interest.

ORCID
Yoshiko Mizushina https://orcid.org/0000-0002-9988-5755
Hiroyoshi Tsubochi https://orcid.org/0000-0002-2174-9454
Yasuhiro Yamaguchi https://orcid.org/0000-0002-6899-4406

REFERENCES
1. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.

2. Kida J, Kanaji N, Kishi S, Imaida K, Bandoh S. An autopsy case of rapidly progressing spindle cell carcinoma of the lung accompanied by intratumor hemorrhage. Am J Case Rep. 2015;16:805–10.

3. Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer. 2015;51:2698–707.

4. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol. 2013;8:803–5.

5. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.

6. Tsurumi K, Kawashima Y, Akahira J, Saito R, Toi Y, Nakamura A, et al. A remarkable clinical response to pembrolizumab in a rare spindle cell carcinoma of the lung. JMA J. 2020;10:83–6.

7. Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase ii study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25:5485–92.

8. Domblides C, Leroy K, Monnet I, Mazieres J, Barlesi F, Gounant V, et al. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma. J Thorac Oncol. 2020;15:860–6.

9. Di Giacomo AM, Valente M, Cerese A, Lofiego MF, Piazzini F, Calabró L, et al. Immunotherapy of brain metastases: breaking a “dogma”. J Exp Clin Cancer Res. 2019;38:419.

10. Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol. 2018;25(Suppl 1):S103–14.

11. Franchino F, Rudá R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161.

12. Kamath SD, Kunthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol. 2018;8:414.

13. Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21:653–63.

14. Di M, Zhang L. Pembrolizumab for non-small cell lung cancer with central nervous system metastases: a two-case report. Thorac Cancer. 2019;10:381–5.

15. Lauto A, Thapa B, Venur VA, Ahluwalia MS. Management of brain metastases in the new era of checkpoint inhibition. Curr Neurol Neurosci Rep. 2018;18:70.

16. Melian M, Lorente D, Aparici F, Juan O. Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment. Thorac Cancer. 2018;9:1770–3.

17. Choiu VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3.

18. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–61.

19. Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol. 2015;22(Suppl 1):S103–4.

20. Lin X, Lu T, Xie Z, Qin Y, Liu M, Xie X, et al. Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: a case report and literature review. Thorac Cancer. 2019;10:1272–5.